Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to ...

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell ...

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for ...

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...

Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring ...

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers ...

Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check ...

Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...